In 2020, while most people were learning how to mute themselves on Zoom, Inquis Medical quietly set up shop in Menlo Park with a very specific problem in its sights. Venous thromboembolic disease is not theoretical, not rare, and not forgiving. Pulmonary embolism and deep vein thrombosis do not wait for consensus or convenience. They demand speed, precision, and respect for blood. That is the lane Inquis Medical chose, and they stayed in it.
Vahid Saadat and Mojgan Saadat did not arrive here by accident. This is what happens when two medical device operators with real scar tissue decide to apply decades of engineering, regulatory, and commercialization lessons to one of medicine’s most unforgiving categories. Inquis Medical was built around a disciplined belief that thrombectomy should be intuitive, blood-conserving, and ruthlessly efficient, because physicians already have enough complexity to manage.
The AVENTUS Precision Thrombectomy System reflects that philosophy end to end. Directional aspiration paired with TrueClot tissue sensing and integrated autologous blood reinfusion is not a marketing bundle. It is a workflow decision. No capital equipment. No multiple exchanges. A system that differentiates clot, blood, and vessel wall in real time changes how operators move, think, and trust the tool in their hands.
The clinical data showed the receipts. 130 patients. 22 sites. 49 principal investigators. Zero device-related major adverse events where 25% was the performance goal. A 0.47 reduction in RV/LV ratio. 35.9% clot burden reduction. Mean ICU stay under 1 day. Blood returned to patients, not lost. That is not noise. That is execution.
Regulatory momentum followed. FDA 510(k) clearance for peripheral vasculature in Nov 2023. Expanded pulmonary embolism clearance in June 2025. A national launch. A lean team of approximately 27 people operating with the urgency of a commercial org and the discipline of a clinical one.
Then Jan 11, 2026 lands with a $75M Series C led by an undisclosed strategic investor, stacking on top of an oversubscribed $40M Series B led by Marshall Wace. Andrew D. Goldberg, MD joins the board, bringing clinical and capital fluency to a group that already understands how products survive real hospitals. Total disclosed funding now sits at $115M, aimed squarely at commercial expansion, clinical evidence, and a pipeline that is clearly not stopping here.
In a market moving toward multi-billion dollar scale, Inquis Medical is not trying to be loud. It is trying to be exact. Exact in diagnosis. Exact in removal. Exact in how blood is handled and returned. Companies built with that level of intent tend to compound quietly, right up until everyone else has to catch up.
